A Combination of Teclistamab and Daratumumab Prolongs PFS in Patients with Relapsed or Refractory Multiple Myeloma By Ogkologos - January 12, 2026 235 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MajesTEC-3 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR New Research on Treating Hormone Receptor-Positive Breast Cancer From SABCS 2020 January 29, 2021 Genetic Testing for Bladder Cancer: What People With Cancer and Their... March 23, 2023 New Generation of Antibody-Drug Conjugates (ADCs) Shows Unprecedented Promise in Early-Stage... October 18, 2025 ΚΑΡΚΙΝΟΣ ΧΟΛΗΔΟΧΟΥ ΚΥΣΤΕΩΣ March 8, 2019 Load more HOT NEWS Outcomes of Cancer Patients with SARS-CoV-2 Infection in Veneto FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA2-mutated Metastatic Castration-Sensitive Prostate Cancer Nivolumab-Based Combinations Improve Survival in Advanced Esophageal Cancer Could A Form of Cell Death Enhance Cancer Immunotherapy?
